[Concomitant use of radiotherapy and gemcitabine: preclinical findings and clinical practice]
| Autor: | Azria D, Coelho M, Larbouret C, Lemanski C, Serre A, Ychou M, André Pèlegrin, Jb, Dubois, Culine S |
|---|---|
| Předmět: |
Male
Antimetabolites Antineoplastic Radiation-Sensitizing Agents Lung Neoplasms Time Factors Uterine Cervical Neoplasms Breast Neoplasms Adenocarcinoma Deoxycytidine Mice Clinical Trials Phase II as Topic Carcinoma Non-Small-Cell Lung Neoplasms Tumor Cells Cultured Animals Humans Randomized Controlled Trials as Topic Clinical Trials Phase I as Topic Radiotherapy Dosage Combined Modality Therapy Gemcitabine Rats Pancreatic Neoplasms Otorhinolaryngologic Neoplasms Urinary Bladder Neoplasms Carcinoma Squamous Cell Female |
| Zdroj: | Europe PubMed Central |
| Popis: | Gemcitabine is pyrimidine analog which has demonstrated antitumoral activity in a variety of solid tumors. Laboratory studies demonstrating that gemcitabine is a potent radiosensitizer led to a variety of trials combining radiation and gemcitabine. In the clinic, phase I-II studies are still trying to determine the optimal dose and schedule which could be use in daily clinical practice. This review summarizes the mechanisms of interaction between radiotherapy and gemcitabine and presents several therapeutic schemes for each tumor location. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|